Celularity (NASDAQ:CELU) Coverage Initiated by Analysts at WBB Securities

WBB Securities assumed coverage on shares of Celularity (NASDAQ:CELU) in a report published on Monday morning,Benzinga reports. The firm issued a speculative buy rating and a $6.00 target price on the stock.

Separately, Wall Street Zen upgraded Celularity to a “sell” rating in a research report on Saturday, August 2nd.

Celularity Stock Performance

Shares of CELU opened at $4.15 on Monday. The company has a market cap of $99.39 million, a PE ratio of -1.57 and a beta of 0.79. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07. The stock has a 50-day moving average price of $2.56 and a 200-day moving average price of $2.05. Celularity has a 12-month low of $1.00 and a 12-month high of $5.22.

Institutional Trading of Celularity

A number of hedge funds have recently bought and sold shares of CELU. Valmark Advisers Inc. bought a new stake in Celularity in the 2nd quarter worth approximately $98,000. Two Sigma Investments LP bought a new stake in Celularity in the 4th quarter worth approximately $93,000. Bank of America Corp DE lifted its position in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Celularity in the first quarter valued at approximately $34,000. Finally, XTX Topco Ltd lifted its position in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after purchasing an additional 11,057 shares during the last quarter. Institutional investors own 19.02% of the company’s stock.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.